Korean J Intern Med > Volume 35(5); 2020 > Article |
|
Characteristic | Total (n = 703) |
PFA closure time |
p value | |
---|---|---|---|---|
Normal (n = 480) | Prolongation (n = 223) | |||
Severity of surgery | 0.757 | |||
Majora | 444 (63.2) | 305 (63.5) | 139 (62.3) | |
Minorb | 259 (36.8) | 175 (36.5) | 84 (37.7) | |
Category of surgery | 0.939 | |||
Orthopedic surgery | 221 (31.4) | 153 (31.9) | 68 (30.5) | |
Abdominal surgery | 227 (32.3) | 155 (32.3) | 72 (32.3) | |
Neurosurgery | 68 (9.7) | 41 (8.5) | 27 (12.1) | |
Thoracic surgery | 44 (6.3) | 34 (7.1) | 10 (4.5) | |
Plastic surgery | 26 (3.7) | 18 (3.8) | 8 (3.6) | |
Gynecological surgery | 25 (3.6) | 16 (3.3) | 9 (4.0) | |
Otolaryngologic surgery | 17 (2.4) | 12 (2.5) | 5 (2.2) | |
Urologic surgery | 13 (1.8) | 9 (1.9) | 4 (1.8) | |
Cardiovascular surgery | 11 (1.6) | 7 (1.5) | 4 (1.8) | |
Ophthalmic surgery | 4 (0.6) | 2 (0.4) | 2 (0.9) | |
Breast surgery | 3 (0.4) | 2 (0.4) | 1 (0.4) | |
Othersc | 44 (6.3) | 31 (6.5) | 13 (5.8) |
a Major surgery: any procedure in which a body cavity was entered, a mesenchymal barrier was crossed, a facial plane was opened, an organ was removed, or normal anatomy was altered.
Characteristic |
COL/EPI |
COL/ADP |
||||
---|---|---|---|---|---|---|
Number | Closure time | p value | Number | Closure time | p value | |
Anti-platelet drug | ||||||
No use | 587 | 154 (35–300) | < 0.001 | 153 | 108 (43–300) | 0.391 |
Aspirin | 59 | 250 (83–300) | 30 | 118 (46–300) | ||
Other antiplatelet | 40 | 177 (86–300) | 18 | 105 (81–300) | ||
Combination | 14 | 265 (109–300) | 8 | 114 (60–300) | ||
NSAID | ||||||
No | 449 | 147 (35–300) | < 0.001 | 111 | 109 (43–300) | 0.249 |
Yes | 251 | 215 (50–300) | 98 | 107 (46–300) | ||
Hemoglobin, g/L | ||||||
≥ 120 | 469 | 153 (56–300) | 0.027 | 126 | 103 (43–300) | < 0.001 |
< 120 | 231 | 181 (35–300) | 83 | 124 (60–300) | ||
Hematocrit, % | ||||||
≥ 35 | 512 | 157 (56–300) | 0.039 | 141 | 103 (43–300) | < 0.001 |
< 35 | 188 | 191 (35–300) | 68 | 131 (60–300) | ||
Platelet count, /L | ||||||
≥ 150 × 109 | 633 | 161 (35–300) | 0.542 | 191 | 108 (43–300) | 0.017 |
< 150 × 109 | 67 | 167 (71–300) | 18 | 116 (89–300) | ||
Blood collection timea | ||||||
Dawn | 87 | 169 (50–300) | 0.004 | 36 | 100 (60–300) | 0.766 |
Morning | 160 | 148 (35–300) | 58 | 107 (45–300) | ||
Afternoon | 303 | 157 (56–300) | 83 | 109 (46–300) | ||
Night | 150 | 186 (81–300) | 35 | 110 (43–300) | ||
Blood group | ||||||
A | 237 | 163 (71–300) | 0.916 | 71 | 100 (46–300) | 0.122 |
B | 192 | 156 (35–300) | 53 | 110 (58–300) | ||
AB | 80 | 152 (68–300) | 24 | 99 (45–300) | ||
O | 191 | 169 (50–300) | 61 | 115 (43–300) |
Values are presented as median (range). Prothrombin time and activated partial thromboplastin time were excluded because the number of abnormal results was too small.
PFA, platelet function analyzer; COL/EPI, collagen/epinephrine; COL/ADP, collagen/adenosine diphosphate; NSAID, nonsteroidal anti-inflammatory drug.